AdAlta（1AD）株式概要臨床段階のバイオテクノロジー企業であるAdAlta Limitedは、オーストラリアでi-bodyプラットフォームによるタンパク質および細胞ベースの治療薬の発見と開発を行っている。 詳細1AD ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬過去5年間の収益は年間2.5%増加しました。 リスク分析意味のある時価総額がありません ( A$8M )マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見る1AD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.0037.4k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-8m4m2016201920222025202620282031Revenue AU$110.2kEarnings AU$20.3kAdvancedSet Fair ValueView all narrativesAdAlta Limited 競合他社NeuroScientific BiopharmaceuticalsSymbol: ASX:NSBMarket cap: AU$21.3mHeximaSymbol: ASX:HXLMarket cap: AU$2.2mNoxopharmSymbol: ASX:NOXMarket cap: AU$24.3mCynata TherapeuticsSymbol: ASX:CYPMarket cap: AU$3.9m価格と性能株価の高値、安値、推移の概要AdAlta過去の株価現在の株価AU$0.00352週高値AU$0.00852週安値AU$0.002ベータ0.191ヶ月の変化-25.00%3ヶ月変化-25.00%1年変化50.00%3年間の変化-87.50%5年間の変化-97.60%IPOからの変化-98.93%最新ニュースお知らせ • Jun 09AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • May 04+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 518,687,262 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Jan 13AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 240,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 20AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 366,666,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 13+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,657,204 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,009,463 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 24AdAlta Limited, Annual General Meeting, Nov 19, 2025AdAlta Limited, Annual General Meeting, Nov 19, 2025. Location: piper alderman, level 23, 459 collins street, melbourne vic 3000, and, Australia最新情報をもっと見るRecent updatesお知らせ • Jun 09AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • May 04+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 518,687,262 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Jan 13AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 240,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 20AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 366,666,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 13+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,657,204 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,009,463 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 24AdAlta Limited, Annual General Meeting, Nov 19, 2025AdAlta Limited, Annual General Meeting, Nov 19, 2025. Location: piper alderman, level 23, 459 collins street, melbourne vic 3000, and, AustraliaNew Risk • Aug 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.9m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-AU$598k). Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Revenue is less than US$1m (AU$696k revenue, or US$453k). Market cap is less than US$10m (AU$4.62m market cap, or US$3.01m).お知らせ • Jun 30Adalta Limited Announces Resignation of Iain Ross as Non-Executive Director, Effective Date Is June 30, 2025AdAlta Limited announced that non-executive director, Iain Ross, has tendered his resignation effective from 30 June 2025 due to the potential for conflicts of interest to emerge between AdAlta and another company he serves.お知らせ • May 01AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.286446 million.AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.286446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 317,148,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,666,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00003 Transaction Features: Rights OfferingNew Risk • Apr 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.9m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (AU$973k revenue, or US$588k). Market cap is less than US$10m (AU$4.50m market cap, or US$2.72m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).New Risk • Feb 21New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: AU$973k (US$623k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.9m free cash flow). Revenue is less than US$1m (AU$973k revenue, or US$623k). Market cap is less than US$10m (AU$9.47m market cap, or US$6.07m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.3m free cash flow). Market cap is less than US$10m (AU$9.47m market cap, or US$5.95m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m).お知らせ • Oct 23AdAlta Limited Appoints Kevin Lynch as Consultant Chief Medical Officer of AdCellaAdAlta Limited announced a significant addition to its AdCella leadership team. Kevin Lynch MB BS has been appointed as Consultant Chief Medical Officer. In this role he will help support the selection of in-licensed cellular immunotherapies and the design and execution of Phase I clinical trials by AdCella. Consultant CMO-AdCella, Kevin Lynch MB BS, based in Australia with leading industry and China haematology/oncology experience. Dr. Lynch has taken on the role of Consultant CMO-AdCella, as this AdAlta subsidiary continues to execute its East to West cellular immunotherapy strategy. Dr. Lynch is a highly experienced industry physician. His 30 years' experience span all stages of clinical development, regulatory and reimbursement approvals and post-registration medical activities. He has contributed to multiple transformational therapies in haematology/oncology at both early- to late-stage therapies, including imatinib, nilotinib, lenalidomide and pomalidomide. He has led high level regulatory interactions in Australia (including for cell therapies), China, South Korea, Singapore, Europe, and other markets. Importantly, he has also provided senior input into multiple interactions with the US Food & Drug Administration (FDA). Dr. Lynch is Co-Founder of PopulusBio srl. His previous leadership roles include CMO at Antengene and senior medical and clinical roles at Celgene and Novartis.お知らせ • Oct 18AdAlta Limited, Annual General Meeting, Nov 20, 2024AdAlta Limited, Annual General Meeting, Nov 20, 2024. Location: at piper alderman, level 23, 459 collins stree, melbourne, 3000, Australia分析記事 • Oct 11Is AdAlta (ASX:1AD) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...New Risk • Jun 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m). Market cap is less than US$100m (AU$16.1m market cap, or US$10.7m).New Risk • Feb 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.2m free cash flow). Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Market cap is less than US$10m (AU$9.99m market cap, or US$6.54m). Minor Risk Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m).お知らせ • Dec 20AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listingお知らせ • Dec 19AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.46 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.46 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct ListingNew Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$5.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.1m free cash flow). Earnings have declined by 0.5% per year over the past 5 years. Market cap is less than US$10m (AU$8.41m market cap, or US$5.49m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m).お知らせ • Nov 03AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million.AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 61,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listingお知らせ • Sep 22AdAlta Limited, Annual General Meeting, Nov 22, 2023AdAlta Limited, Annual General Meeting, Nov 22, 2023, at 11:01 AUS Eastern Standard Time. Location: Piper Alderman, Level 23, 459 Collins Street Melbourne Victoria Australia Agenda: To provide business update to Shareholders.New Risk • Aug 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$5.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.1m free cash flow). Earnings have declined by 0.5% per year over the past 5 years. Market cap is less than US$10m (AU$10.2m market cap, or US$6.51m). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m).お知らせ • Jul 13AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 51,303,619 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 74,846,752 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Rights OfferingReported Earnings • Mar 03First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.015 loss in 1H 2022). Revenue: AU$1.11m (up 53% from 1H 2022). Net loss: AU$2.82m (loss narrowed 23% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.分析記事 • Nov 16Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For NowShareholders of AdAlta Limited ( ASX:1AD ) will have been dismayed by the negative share price return over the last...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Bob Peach was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 03AdAlta Limited Provides an Update on Its Lead Program, AD-214AdAlta Limited provided an update on its lead program, AD-214, a first in class antifibrotic. AdAlta has made substantial progress expanding the potential disease areas (indications) and routes of delivery for AD-214. Considering available manufacturing and toxicology study slots and return on investment, AdAlta is now progressing four strategic priorities for AD-214. Prioritise clinical development of AD-214 for lung, kidney and eye fibrosis. Pre-clinical data and partnering discussions over the next six months to guide final choice of indication for next clinical trial. Progress injectable (intravenous/IV for lung, kidney fibrosis and intravitreal/IVT for eye fibrosis) routes of administration. Continue investment in manufacturing and formulation improvement strategies. Leverage progress in the development of an inhaled format of AD-214 for partnering for lung fibrosis. Several disease area opportunities - all with unmet need: To prioritise indications and routes of administration, AdAlta considered the unmet needs in each disease area and the competitive landscape. Also considered was the data, available or pending, supporting use of AD-214 in each indication, and the time and cost to progress each indication and route of administration to clinical proof of concept. AdAlta has compelling pre-clinical data using the IV version of AD-214 in lung and kidney fibrosis. Like lung fibrosis, kidney fibrosis is an area of high unmet need with a less competitive landscape. Progress to Phase II proof of concept studies using the IV version is underpinned by previously completed Phase I studies and encouraging progress made identifying opportunities to increase manufacturing yields and reduce liver clearance. Intravitreal (IVT) AD-214 could address an attractive, very underserved market in eye fibrosis with significant early stage partnering interest and a more favourable competitive landscape. Previous encouraging pre-clinical studies using the earlier version of the product, AD-114, are being replicated and extended using AD-214, with results due in the next six months. IVT AD-214 (intravitreal) could be progressed separately to IV AD-214 (intravenous) through engagement with partners, or by AdAlta directly. It has the potential to achieve clinical proof of concept via Phase I studies. Recent collaboration with GPCR Therapeutics for oncology Oncology is now the largest therapeutic market globally. The application of CXCR4 antagonists such as AD-214 to treat cancer is attracting significant interest. The recently announced collaboration with GPCR Therapeutics Inc. represents a cost-effective way for AdAlta to progress an oncology pipeline. Inhaled AD-214 - valuable data package for potential partners: AdAlta has now demonstrated the delivery of AD-214 via inhalation and the potential to reduce collagen deposition in cultured lung tissue. The additional time and cost to complete preclinical development and safety studies for IPF, coupled with the competitive clinical trial landscape has led the Company to focus resources on injectable formats and make the inhalation program available to lung fibrosis partners to progress. Next steps: AD-214 milestones in the next six months now include: Commencement of manufacturing of AD-214 for extended-dose toxicology studies; Additional pre-clinical results in eye and kidney fibrosis; Further details on clinical program indication and design; Continuation of partnering outreach for IV AD-214 in lung and kidney fibrosis.お知らせ • Sep 29AdAlta Limited, Annual General Meeting, Nov 22, 2022AdAlta Limited, Annual General Meeting, Nov 22, 2022, at 11:01 AUS Eastern Standard Time. Location: K&L Gates, Level 25, Rialto South Tower Melbourne Victoria Australia分析記事 • Sep 02Is AdAlta (ASX:1AD) Using Debt Sensibly?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.024 loss in FY 2021)Full year 2022 results: AU$0.022 loss per share. Revenue: AU$2.76m (down 31% from FY 2021). Net loss: AU$6.06m (loss widened 7.7% from FY 2021).お知らせ • Jul 04AdAlta Limited Modifies the Sequencing of AD-214 Manufacturing Campaigns and Toxicology StudiesAdAlta Limited has modified the sequencing of AD-214 manufacturing campaigns and toxicology studies to better align these key programs with the emerging priorities of potential partners, and the results of pre-clinical studies due in the September quarter 2022. The Company has been able to secure a six-month deferral of pre-booked manufacturing campaigns and toxicology studies, which also ensures that AdAlta can delay financial commitments to these studies, extending its existing cash runway. The optimal volume of AD-214 to be manufactured for future toxicology and clinical studies, the final formulation step in manufacturing, and the optimal design of toxicology studies vary according to the indication to be studied in future clinical trials. The different disease area and geographic interests of different potential partners and the data that will become available through the September quarter 2022 will help shape AdAlta's formulation and partnering strategy. To ensure that its manufacturing campaigns and toxicology studies are designed to maximise the development options for, and hence value of, AD-214, the Company has negotiated a 6-month deferral of AD-214 production and toxicology campaigns to maximise decision- making flexibility and ensure that these significant cash commitments are made with the benefit of the maximum amount of pre-clinical data and confirmed partner indication priorities. Clinical timelines are expected be delayed by a lesser amount. AdAlta will now not need to commit cash to the next round of manufacturing and toxicology costs until the end of 2022. The changes to the program as outlined above have accordingly extended the company's cash runway.Price Target Changed • Apr 27Price target increased to AU$0.27Up from AU$0.18, the current price target is provided by 1 analyst. New target price is 297% above last closing price of AU$0.068. Stock is down 55% over the past year. The company posted a net loss per share of AU$0.024 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Bob Peach was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 06Adalta Limited Finalizes Reclinical Development Program to Develop Inhaled Version of AD-214AdAlta Limited has finalised the preclinical development program to develop an inhaled version of AD-214, its lead asset. AD-214 is being developed as a first in class therapeutic for fibrotic diseases including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILDs). In July 2021, AdAlta announced the successful completion of a Phase I clinical trial assessing the safety and tolerability of AD-214 in healthy volunteers, the securing of production slots to deliver the next batch of clinical grade AD-214 in mid-2023 and that it would use the intervening period to develop a more patient convenient, lower cost inhaled formulation of AD-214. AdAlta has now finished mapping out the preclinical development plan for the inhaled formulation of AD-214. The development plan addresses three questions: 1. Delivery: can nebulised AD-214 reach the lower airways of the lungs intact? 2. Distribution and retention: can AD-214, once in the lower airways of the lungs, reach and be retained in fibrotic tissue? 3. Efficacy: can AD-214 moderate fibrotic disease progression when delivered directly to fibrotic lung tissue? The ongoing and planned experiments to address these questions are anticipated to produce a steady flow of data between now and completion in the September quarter. Delivery, distribution and retention will be studied using PET imaging and pathology studies in both animal and in vitro cultured tissue models. In vivo efficacy studies include the gold standard bleomycin mouse model of IPF. Data from this study has been delayed due to technical difficulties establishing a fibrosis baseline in the first attempt. This is not an uncommon issue for studies of this kind. This study will be repeated without affecting overall timelines. In vivo efficacy studies will be supported by in vitro studies in human lung airway cells and in cultured human lung tissue. They will be further complemented by results from studies of AD-214 in animal models of other fibrotic diseases (kidney and eye). Work to optimise a formulation of AD-214 for nebulisation and inhalation is expected to be completed in parallel with the preclinical studies, enabling large animal toxicology studies to be initiated in the March quarter of 2023. Assuming success, these will in turn enable the next clinical studies to commence in the second half of 2023 as previously announced. Next clinical studies are anticipated to comprise an initial healthy volunteer bridging safety study which will be combined with IPF patient imaging studies using the already developed radiolabelled (for PET imaging) version of AD-214 ahead of efficacy studies in IPF patients. In delivering this program, AdAlta is leveraging significant global expertise in inhaled drug delivery: Arrangements are being finalised to conduct imaging studies of AD-214 distribution and retention with Allergenix Pty Ltd. (Australia), a preclinical contract research organisation (CRO) specialising in sheep models of pulmonary drug delivery and pulmonary disease including asthma, COPD and fibrosis. Sheep lungs are structurally very similar to human lungs; Dr. Louise Organ, who developed the sheep IPF model and has extensive experience using cultured human lung tissue to model the activity of anti-fibrotic agents, has recently joined the AdAlta team and will lead these studies; Prof Antje Prasse, a world recognised IPF researcher at the Fraunhofer Institute (Germany), has previously shown that AD-114, the i-body incorporated into AD-214, can inhibit the growth of spheroids from cells collected from the lining of the airways in IPF patients, and is now repeating these studies using AD-214; Contracts are being finalised with a new contract research organisation to overcome the technical difficulties associated with establishing fibrosis in the bleomycin mouse model of IPF to further explore distribution, retention and anti-fibrotic effect of AD-214 directly delivered to the lungs; Specialist inhalation contract manufacturing firm, Vectura Ltd. (UK), has been contracted to optimise a formulation of AD-214 for nebulisation and inhalation; ITR Laboratories Canada Inc. (Canada) has been contracted for inhaled toxicology studies.Reported Earnings • Feb 28First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst half 2022 results: AU$0.015 loss per share (up from AU$0.021 loss in 1H 2021). Revenue: AU$727.3k (down 9.8% from 1H 2021). Net loss: AU$3.66m (loss narrowed 19% from 1H 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 2.0%. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.お知らせ • Feb 05AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million. Security Name: Ordianry Share Security Type: Common Stock Securities Offered: 17,169,940 Price\Range: AUD 0.073 Discount Per Security: AUD 0.00438 Transaction Features: Rights OfferingReported Earnings • Aug 29Full year 2021 earnings released: AU$0.024 loss per share (vs AU$0.037 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$3.99m (up 4.2% from FY 2020). Net loss: AU$5.63m (loss narrowed 6.3% from FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.分析記事 • Jun 11We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Mar 03First half 2021 earnings released: AU$0.021 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$806.5k (up 100% from 1H 2020). Net loss: AU$4.51m (loss narrowed 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.分析記事 • Feb 26Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, AdAlta ( ASX:1AD...お知らせ • Feb 24AdAlta Receives Orphan Drug Designation from the US Food and Drug Administration for Its Lead Product Candidate AD-214 for the Treatment of Idiopathic Pulmonary FibrosisAdAlta Limited has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead product candidate AD-214 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The Food and Drug Administration (FDA) created the Orphan Drug Act to encourage and provide special incentives to biopharmaceutical companies that undertake the development of promising potential treatments for rare or `orphan' diseases that affect fewer than 200,000 people in the United States. ODD entitles AD-214 to certain benefits during development for IPF including eligibility for seven years market exclusivity post approval, tax credits of 50% of qualified clinical drug testing costs awarded upon approval, additional protocol assistance, reduced review times and waiver of certain marketing authorisation application fees. In addition to bringing novel therapies to sufferers of rare diseases more rapidly, these benefits add additional economic value to AD-214 for AdAlta and its eventual commercialisation partners. The grant of ODD for AD-214 follows the previous grant of ODD for AD-114, the predecessor molecule to AD-214.お知らせ • Dec 15AdAlta Limited Announces Phase I HV Extension to Explore Encouraging ResultsAdAlta Limited, a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets will extend the healthy volunteer Part A of its Phase I clinical study of AD-214 to explore encouraging results from cohorts studied to date. AdAlta has now treated 34 healthy volunteers with lead product candidate AD-214 or placebo at doses ranging from 0.01 mg.kg to 10 mg/kg. The Safety Management Committee has found no adverse safety events of clinical concern and has now approved dose escalation to 20 mg/kg, the maximum planned dose in Part A of the Phase I clinical study. A key secondary endpoint of the Phase I study is the extent and duration of receptor occupancy, the percentage of target receptors on certain circulating white blood cells that are occupied by AD-214. High levels of receptor occupancy are generally required for therapeutic effect of any drug and the time over which receptor occupancy remains high is a key indicator of likely therapeutic dosing intervals (with longer intervals generally more convenient and lower cost). Throughout Part A of the Phase I study, AdAlta has observed a dose dependent increase in both the duration of white blood cell receptor saturation (100% receptor occupancy) and the time receptor occupancy remains above 50%. Blinded data from the most recent cohorts at 5 and 10 mg/kg shows that receptors remained saturated for three days after infusion of AD-214 and remained at 55% ± 14% and 86% ± 11% at seven days after infusion respectively.お知らせ • Sep 23AdAlta Limited Announces the Extension of its Collaboration with GE HealthcareAdAlta Limited announced the extension of its collaboration with global life sciences company GE Healthcare. AdAlta and GE Healthcare have confirmed that their collaboration to discover i-body candidates as diagnostic imaging agents for granzyme B will proceed to Stage 4 of a multistage collaboration. AdAlta has to date earned an initial milestone payment and research fees for the first three stages of the collaboration. These stages have yielded a panel of i-bodies with affinity, specificity and activity properties against granzyme B that warrant further development. GE Healthcare is a leading global medical technology and pharmaceutical company, providing a broad portfolio of products, solutions and services used in the diagnosis, treatment and monitoring of patients. Granzyme B is a key biomarker of response to cancer immunotherapy. GE Healthcare has exercised an option under the collaboration agreement to progress to Stage 4 during which the panel of i-bodies selected in Stage 3 and those closely related to them will be further characterised, prior to GE Healthcare progressing a lead i-body into pre-clinical development. The research fees for Stage 4 will be paid in instalments over the six months commencing in November 2020.お知らせ • Sep 08AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,000,000 Price\Range: AUD 0.1 Discount Per Security: AUD 0.006 Transaction Features: Subsequent Direct Listingお知らせ • Sep 07AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,986,403 Price\Range: AUD 0.1 Discount Per Security: AUD 0.003 Transaction Features: Regulation S; Rights Offering株主還元1ADAU BiotechsAU 市場7D0%5.7%-1.4%1Y50.0%-49.7%2.2%株主還元を見る業界別リターン: 1AD過去 1 年間で-49.7 % の収益を上げたAustralian Biotechs業界を上回りました。リターン対市場: 1AD過去 1 年間で2.2 % の収益を上げたAustralian市場を上回りました。価格変動Is 1AD's price volatile compared to industry and market?1AD volatility1AD Average Weekly Movement19.4%Biotechs Industry Average Movement10.6%Market Average Movement10.1%10% most volatile stocks in AU Market17.3%10% least volatile stocks in AU Market4.0%安定した株価: 1ADの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1ADの 週次ボラティリティ は過去 1 年間で31%から19%に減少しましたが、依然としてAustralian株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20061Tim Oldhamwww.adalta.com.au臨床段階のバイオテクノロジー企業であるAdAlta Limitedは、オーストラリアでi-bodyプラットフォームによるタンパク質および細胞ベースの治療薬を発見・開発している。同社の主力製品はAD-214で、特発性肺線維症、眼線維症、肝臓・皮膚・腎臓の線維症、加齢黄斑変性症などの線維症治療薬として第II相臨床試験中である。ラ・トローブ大学との共同研究により、マラリア複数種、バベシア、トキソプラズマに対するWD-34を発見した。同社は2006年に法人化され、オーストラリアのキャンバーウェルに拠点を置いている。もっと見るAdAlta Limited 基礎のまとめAdAlta の収益と売上を時価総額と比較するとどうか。1AD 基礎統計学時価総額AU$7.97m収益（TTM）-AU$4.36m売上高(TTM)AU$608.07k13.1xP/Sレシオ-1.8xPER（株価収益率1AD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1AD 損益計算書（TTM）収益AU$608.07k売上原価AU$219.37k売上総利益AU$388.71kその他の費用AU$4.75m収益-AU$4.36m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0016グロス・マージン63.92%純利益率-717.51%有利子負債／自己資本比率0%1AD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/24 15:11終値2026/06/24 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AdAlta Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Maxim JacobsEdison Investment ResearchScott PowerMorgans Financial LimitedDerek JellinekMorgans Financial Limited
お知らせ • Jun 09AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • May 04+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 518,687,262 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Jan 13AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 240,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 20AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 366,666,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 13+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,657,204 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,009,463 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 24AdAlta Limited, Annual General Meeting, Nov 19, 2025AdAlta Limited, Annual General Meeting, Nov 19, 2025. Location: piper alderman, level 23, 459 collins street, melbourne vic 3000, and, Australia
お知らせ • Jun 09AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.425251 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • May 04+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 106,312,738 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 518,687,262 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Jan 13AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 240,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 20AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 366,666,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 13+ 1 more updateAdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,657,204 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,009,463 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 24AdAlta Limited, Annual General Meeting, Nov 19, 2025AdAlta Limited, Annual General Meeting, Nov 19, 2025. Location: piper alderman, level 23, 459 collins street, melbourne vic 3000, and, Australia
New Risk • Aug 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.9m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-AU$598k). Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Revenue is less than US$1m (AU$696k revenue, or US$453k). Market cap is less than US$10m (AU$4.62m market cap, or US$3.01m).
お知らせ • Jun 30Adalta Limited Announces Resignation of Iain Ross as Non-Executive Director, Effective Date Is June 30, 2025AdAlta Limited announced that non-executive director, Iain Ross, has tendered his resignation effective from 30 June 2025 due to the potential for conflicts of interest to emerge between AdAlta and another company he serves.
お知らせ • May 01AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.286446 million.AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.286446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 317,148,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,666,667 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00003 Transaction Features: Rights Offering
New Risk • Apr 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.9m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (AU$973k revenue, or US$588k). Market cap is less than US$10m (AU$4.50m market cap, or US$2.72m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).
New Risk • Feb 21New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: AU$973k (US$623k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.9m free cash flow). Revenue is less than US$1m (AU$973k revenue, or US$623k). Market cap is less than US$10m (AU$9.47m market cap, or US$6.07m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).
New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.3m free cash flow). Market cap is less than US$10m (AU$9.47m market cap, or US$5.95m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (AU$1.7m revenue, or US$1.1m).
お知らせ • Oct 23AdAlta Limited Appoints Kevin Lynch as Consultant Chief Medical Officer of AdCellaAdAlta Limited announced a significant addition to its AdCella leadership team. Kevin Lynch MB BS has been appointed as Consultant Chief Medical Officer. In this role he will help support the selection of in-licensed cellular immunotherapies and the design and execution of Phase I clinical trials by AdCella. Consultant CMO-AdCella, Kevin Lynch MB BS, based in Australia with leading industry and China haematology/oncology experience. Dr. Lynch has taken on the role of Consultant CMO-AdCella, as this AdAlta subsidiary continues to execute its East to West cellular immunotherapy strategy. Dr. Lynch is a highly experienced industry physician. His 30 years' experience span all stages of clinical development, regulatory and reimbursement approvals and post-registration medical activities. He has contributed to multiple transformational therapies in haematology/oncology at both early- to late-stage therapies, including imatinib, nilotinib, lenalidomide and pomalidomide. He has led high level regulatory interactions in Australia (including for cell therapies), China, South Korea, Singapore, Europe, and other markets. Importantly, he has also provided senior input into multiple interactions with the US Food & Drug Administration (FDA). Dr. Lynch is Co-Founder of PopulusBio srl. His previous leadership roles include CMO at Antengene and senior medical and clinical roles at Celgene and Novartis.
お知らせ • Oct 18AdAlta Limited, Annual General Meeting, Nov 20, 2024AdAlta Limited, Annual General Meeting, Nov 20, 2024. Location: at piper alderman, level 23, 459 collins stree, melbourne, 3000, Australia
分析記事 • Oct 11Is AdAlta (ASX:1AD) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
New Risk • Jun 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m). Market cap is less than US$100m (AU$16.1m market cap, or US$10.7m).
New Risk • Feb 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.2m free cash flow). Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Market cap is less than US$10m (AU$9.99m market cap, or US$6.54m). Minor Risk Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m).
お知らせ • Dec 20AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 19AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.46 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 0.46 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$5.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.1m free cash flow). Earnings have declined by 0.5% per year over the past 5 years. Market cap is less than US$10m (AU$8.41m market cap, or US$5.49m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m).
お知らせ • Nov 03AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million.AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 61,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 22AdAlta Limited, Annual General Meeting, Nov 22, 2023AdAlta Limited, Annual General Meeting, Nov 22, 2023, at 11:01 AUS Eastern Standard Time. Location: Piper Alderman, Level 23, 459 Collins Street Melbourne Victoria Australia Agenda: To provide business update to Shareholders.
New Risk • Aug 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$5.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.1m free cash flow). Earnings have declined by 0.5% per year over the past 5 years. Market cap is less than US$10m (AU$10.2m market cap, or US$6.51m). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (AU$3.5m revenue, or US$2.3m).
お知らせ • Jul 13AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 51,303,619 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 74,846,752 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Rights Offering
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)First half 2023 results: AU$0.009 loss per share (improved from AU$0.015 loss in 1H 2022). Revenue: AU$1.11m (up 53% from 1H 2022). Net loss: AU$2.82m (loss narrowed 23% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
分析記事 • Nov 16Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For NowShareholders of AdAlta Limited ( ASX:1AD ) will have been dismayed by the negative share price return over the last...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Bob Peach was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 03AdAlta Limited Provides an Update on Its Lead Program, AD-214AdAlta Limited provided an update on its lead program, AD-214, a first in class antifibrotic. AdAlta has made substantial progress expanding the potential disease areas (indications) and routes of delivery for AD-214. Considering available manufacturing and toxicology study slots and return on investment, AdAlta is now progressing four strategic priorities for AD-214. Prioritise clinical development of AD-214 for lung, kidney and eye fibrosis. Pre-clinical data and partnering discussions over the next six months to guide final choice of indication for next clinical trial. Progress injectable (intravenous/IV for lung, kidney fibrosis and intravitreal/IVT for eye fibrosis) routes of administration. Continue investment in manufacturing and formulation improvement strategies. Leverage progress in the development of an inhaled format of AD-214 for partnering for lung fibrosis. Several disease area opportunities - all with unmet need: To prioritise indications and routes of administration, AdAlta considered the unmet needs in each disease area and the competitive landscape. Also considered was the data, available or pending, supporting use of AD-214 in each indication, and the time and cost to progress each indication and route of administration to clinical proof of concept. AdAlta has compelling pre-clinical data using the IV version of AD-214 in lung and kidney fibrosis. Like lung fibrosis, kidney fibrosis is an area of high unmet need with a less competitive landscape. Progress to Phase II proof of concept studies using the IV version is underpinned by previously completed Phase I studies and encouraging progress made identifying opportunities to increase manufacturing yields and reduce liver clearance. Intravitreal (IVT) AD-214 could address an attractive, very underserved market in eye fibrosis with significant early stage partnering interest and a more favourable competitive landscape. Previous encouraging pre-clinical studies using the earlier version of the product, AD-114, are being replicated and extended using AD-214, with results due in the next six months. IVT AD-214 (intravitreal) could be progressed separately to IV AD-214 (intravenous) through engagement with partners, or by AdAlta directly. It has the potential to achieve clinical proof of concept via Phase I studies. Recent collaboration with GPCR Therapeutics for oncology Oncology is now the largest therapeutic market globally. The application of CXCR4 antagonists such as AD-214 to treat cancer is attracting significant interest. The recently announced collaboration with GPCR Therapeutics Inc. represents a cost-effective way for AdAlta to progress an oncology pipeline. Inhaled AD-214 - valuable data package for potential partners: AdAlta has now demonstrated the delivery of AD-214 via inhalation and the potential to reduce collagen deposition in cultured lung tissue. The additional time and cost to complete preclinical development and safety studies for IPF, coupled with the competitive clinical trial landscape has led the Company to focus resources on injectable formats and make the inhalation program available to lung fibrosis partners to progress. Next steps: AD-214 milestones in the next six months now include: Commencement of manufacturing of AD-214 for extended-dose toxicology studies; Additional pre-clinical results in eye and kidney fibrosis; Further details on clinical program indication and design; Continuation of partnering outreach for IV AD-214 in lung and kidney fibrosis.
お知らせ • Sep 29AdAlta Limited, Annual General Meeting, Nov 22, 2022AdAlta Limited, Annual General Meeting, Nov 22, 2022, at 11:01 AUS Eastern Standard Time. Location: K&L Gates, Level 25, Rialto South Tower Melbourne Victoria Australia
分析記事 • Sep 02Is AdAlta (ASX:1AD) Using Debt Sensibly?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.024 loss in FY 2021)Full year 2022 results: AU$0.022 loss per share. Revenue: AU$2.76m (down 31% from FY 2021). Net loss: AU$6.06m (loss widened 7.7% from FY 2021).
お知らせ • Jul 04AdAlta Limited Modifies the Sequencing of AD-214 Manufacturing Campaigns and Toxicology StudiesAdAlta Limited has modified the sequencing of AD-214 manufacturing campaigns and toxicology studies to better align these key programs with the emerging priorities of potential partners, and the results of pre-clinical studies due in the September quarter 2022. The Company has been able to secure a six-month deferral of pre-booked manufacturing campaigns and toxicology studies, which also ensures that AdAlta can delay financial commitments to these studies, extending its existing cash runway. The optimal volume of AD-214 to be manufactured for future toxicology and clinical studies, the final formulation step in manufacturing, and the optimal design of toxicology studies vary according to the indication to be studied in future clinical trials. The different disease area and geographic interests of different potential partners and the data that will become available through the September quarter 2022 will help shape AdAlta's formulation and partnering strategy. To ensure that its manufacturing campaigns and toxicology studies are designed to maximise the development options for, and hence value of, AD-214, the Company has negotiated a 6-month deferral of AD-214 production and toxicology campaigns to maximise decision- making flexibility and ensure that these significant cash commitments are made with the benefit of the maximum amount of pre-clinical data and confirmed partner indication priorities. Clinical timelines are expected be delayed by a lesser amount. AdAlta will now not need to commit cash to the next round of manufacturing and toxicology costs until the end of 2022. The changes to the program as outlined above have accordingly extended the company's cash runway.
Price Target Changed • Apr 27Price target increased to AU$0.27Up from AU$0.18, the current price target is provided by 1 analyst. New target price is 297% above last closing price of AU$0.068. Stock is down 55% over the past year. The company posted a net loss per share of AU$0.024 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Bob Peach was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 06Adalta Limited Finalizes Reclinical Development Program to Develop Inhaled Version of AD-214AdAlta Limited has finalised the preclinical development program to develop an inhaled version of AD-214, its lead asset. AD-214 is being developed as a first in class therapeutic for fibrotic diseases including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILDs). In July 2021, AdAlta announced the successful completion of a Phase I clinical trial assessing the safety and tolerability of AD-214 in healthy volunteers, the securing of production slots to deliver the next batch of clinical grade AD-214 in mid-2023 and that it would use the intervening period to develop a more patient convenient, lower cost inhaled formulation of AD-214. AdAlta has now finished mapping out the preclinical development plan for the inhaled formulation of AD-214. The development plan addresses three questions: 1. Delivery: can nebulised AD-214 reach the lower airways of the lungs intact? 2. Distribution and retention: can AD-214, once in the lower airways of the lungs, reach and be retained in fibrotic tissue? 3. Efficacy: can AD-214 moderate fibrotic disease progression when delivered directly to fibrotic lung tissue? The ongoing and planned experiments to address these questions are anticipated to produce a steady flow of data between now and completion in the September quarter. Delivery, distribution and retention will be studied using PET imaging and pathology studies in both animal and in vitro cultured tissue models. In vivo efficacy studies include the gold standard bleomycin mouse model of IPF. Data from this study has been delayed due to technical difficulties establishing a fibrosis baseline in the first attempt. This is not an uncommon issue for studies of this kind. This study will be repeated without affecting overall timelines. In vivo efficacy studies will be supported by in vitro studies in human lung airway cells and in cultured human lung tissue. They will be further complemented by results from studies of AD-214 in animal models of other fibrotic diseases (kidney and eye). Work to optimise a formulation of AD-214 for nebulisation and inhalation is expected to be completed in parallel with the preclinical studies, enabling large animal toxicology studies to be initiated in the March quarter of 2023. Assuming success, these will in turn enable the next clinical studies to commence in the second half of 2023 as previously announced. Next clinical studies are anticipated to comprise an initial healthy volunteer bridging safety study which will be combined with IPF patient imaging studies using the already developed radiolabelled (for PET imaging) version of AD-214 ahead of efficacy studies in IPF patients. In delivering this program, AdAlta is leveraging significant global expertise in inhaled drug delivery: Arrangements are being finalised to conduct imaging studies of AD-214 distribution and retention with Allergenix Pty Ltd. (Australia), a preclinical contract research organisation (CRO) specialising in sheep models of pulmonary drug delivery and pulmonary disease including asthma, COPD and fibrosis. Sheep lungs are structurally very similar to human lungs; Dr. Louise Organ, who developed the sheep IPF model and has extensive experience using cultured human lung tissue to model the activity of anti-fibrotic agents, has recently joined the AdAlta team and will lead these studies; Prof Antje Prasse, a world recognised IPF researcher at the Fraunhofer Institute (Germany), has previously shown that AD-114, the i-body incorporated into AD-214, can inhibit the growth of spheroids from cells collected from the lining of the airways in IPF patients, and is now repeating these studies using AD-214; Contracts are being finalised with a new contract research organisation to overcome the technical difficulties associated with establishing fibrosis in the bleomycin mouse model of IPF to further explore distribution, retention and anti-fibrotic effect of AD-214 directly delivered to the lungs; Specialist inhalation contract manufacturing firm, Vectura Ltd. (UK), has been contracted to optimise a formulation of AD-214 for nebulisation and inhalation; ITR Laboratories Canada Inc. (Canada) has been contracted for inhaled toxicology studies.
Reported Earnings • Feb 28First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst half 2022 results: AU$0.015 loss per share (up from AU$0.021 loss in 1H 2021). Revenue: AU$727.3k (down 9.8% from 1H 2021). Net loss: AU$3.66m (loss narrowed 19% from 1H 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 2.0%. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
お知らせ • Feb 05AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million. Security Name: Ordianry Share Security Type: Common Stock Securities Offered: 17,169,940 Price\Range: AUD 0.073 Discount Per Security: AUD 0.00438 Transaction Features: Rights Offering
Reported Earnings • Aug 29Full year 2021 earnings released: AU$0.024 loss per share (vs AU$0.037 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: AU$3.99m (up 4.2% from FY 2020). Net loss: AU$5.63m (loss narrowed 6.3% from FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
分析記事 • Jun 11We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Mar 03First half 2021 earnings released: AU$0.021 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: AU$806.5k (up 100% from 1H 2020). Net loss: AU$4.51m (loss narrowed 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
分析記事 • Feb 26Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, AdAlta ( ASX:1AD...
お知らせ • Feb 24AdAlta Receives Orphan Drug Designation from the US Food and Drug Administration for Its Lead Product Candidate AD-214 for the Treatment of Idiopathic Pulmonary FibrosisAdAlta Limited has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead product candidate AD-214 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The Food and Drug Administration (FDA) created the Orphan Drug Act to encourage and provide special incentives to biopharmaceutical companies that undertake the development of promising potential treatments for rare or `orphan' diseases that affect fewer than 200,000 people in the United States. ODD entitles AD-214 to certain benefits during development for IPF including eligibility for seven years market exclusivity post approval, tax credits of 50% of qualified clinical drug testing costs awarded upon approval, additional protocol assistance, reduced review times and waiver of certain marketing authorisation application fees. In addition to bringing novel therapies to sufferers of rare diseases more rapidly, these benefits add additional economic value to AD-214 for AdAlta and its eventual commercialisation partners. The grant of ODD for AD-214 follows the previous grant of ODD for AD-114, the predecessor molecule to AD-214.
お知らせ • Dec 15AdAlta Limited Announces Phase I HV Extension to Explore Encouraging ResultsAdAlta Limited, a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets will extend the healthy volunteer Part A of its Phase I clinical study of AD-214 to explore encouraging results from cohorts studied to date. AdAlta has now treated 34 healthy volunteers with lead product candidate AD-214 or placebo at doses ranging from 0.01 mg.kg to 10 mg/kg. The Safety Management Committee has found no adverse safety events of clinical concern and has now approved dose escalation to 20 mg/kg, the maximum planned dose in Part A of the Phase I clinical study. A key secondary endpoint of the Phase I study is the extent and duration of receptor occupancy, the percentage of target receptors on certain circulating white blood cells that are occupied by AD-214. High levels of receptor occupancy are generally required for therapeutic effect of any drug and the time over which receptor occupancy remains high is a key indicator of likely therapeutic dosing intervals (with longer intervals generally more convenient and lower cost). Throughout Part A of the Phase I study, AdAlta has observed a dose dependent increase in both the duration of white blood cell receptor saturation (100% receptor occupancy) and the time receptor occupancy remains above 50%. Blinded data from the most recent cohorts at 5 and 10 mg/kg shows that receptors remained saturated for three days after infusion of AD-214 and remained at 55% ± 14% and 86% ± 11% at seven days after infusion respectively.
お知らせ • Sep 23AdAlta Limited Announces the Extension of its Collaboration with GE HealthcareAdAlta Limited announced the extension of its collaboration with global life sciences company GE Healthcare. AdAlta and GE Healthcare have confirmed that their collaboration to discover i-body candidates as diagnostic imaging agents for granzyme B will proceed to Stage 4 of a multistage collaboration. AdAlta has to date earned an initial milestone payment and research fees for the first three stages of the collaboration. These stages have yielded a panel of i-bodies with affinity, specificity and activity properties against granzyme B that warrant further development. GE Healthcare is a leading global medical technology and pharmaceutical company, providing a broad portfolio of products, solutions and services used in the diagnosis, treatment and monitoring of patients. Granzyme B is a key biomarker of response to cancer immunotherapy. GE Healthcare has exercised an option under the collaboration agreement to progress to Stage 4 during which the panel of i-bodies selected in Stage 3 and those closely related to them will be further characterised, prior to GE Healthcare progressing a lead i-body into pre-clinical development. The research fees for Stage 4 will be paid in instalments over the six months commencing in November 2020.
お知らせ • Sep 08AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,000,000 Price\Range: AUD 0.1 Discount Per Security: AUD 0.006 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 07AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million.AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,986,403 Price\Range: AUD 0.1 Discount Per Security: AUD 0.003 Transaction Features: Regulation S; Rights Offering
